

Haematologica
HAEMATOL/2016/150433
Version 3

Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model

Mark R. Hanudel, Maxime Rappaport, Victoria Gabayan, Grace Jung, Isidro B. Salusky, Elizabeta Nemeth, Tomas Ganz, and Joshua Zaritsky

Disclosures: IBS has served as a consultant for or received honoraria from Sanofi, Abbvie, Amgen, OPKD Health, and Keryx Biopharmaceuticals. EN and TG are shareholders of Intrinsic LifeSciences, a company developing hepcidin diagnostics; Merganser Biotech, a company developing hepcidin-based therapeutics; and Silarus Therapeutics, a company developing erythroferrone-based therapies. TG has also served as a consultant for Keryx Biopharmaceuticals. This work was supported in part by USPHS Grants DK-67563, DK-35423, DK-80984; NIH/NCATS/UCLA CTSI Grant UL1 TR-000124; NIH K12 Child Health Research Career Development Award K12-HD-034610; NIH Training Grant T32-DK-07789; and funds from the UCLA Children's Discovery and Innovation Institute.

Contributions: MRH, MR, VG, GJ, and JZ performed research; MRH, EN, and JZ performed data analysis; MRH, IBS, EN, and TG wrote the manuscript; IBS, EN, TG, and JZ supervised the study.